Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HHAT | Q5VTY9 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794897 | 1.00 | LMNA (0.45) | LMNAHTTTAAR1POLBL3MBTL1 | |
| SCHEMBL3229624 | 0.94 | L3MBTL1 (0.48) | LMNAL3MBTL1TP53HHATSTAT3 | |
| SCHEMBL30795350 | 0.94 | L3MBTL1 (0.48) | LMNAL3MBTL1TP53HHATSTAT3 | |
| SCHEMBL30794736 | 0.90 | LMNA (0.46) | LMNAL3MBTL1TP53HHATCYP2D6 | |
| SCHEMBL3242933 | 0.90 | LMNA (0.46) | LMNAL3MBTL1TP53HHATCYP2D6 | |
| SCHEMBL30796399 | 0.90 | HHAT (0.43) | LMNAHTTHHATCYP2D6STAT3 | |
| SCHEMBL3238924 | 0.90 | HHAT (0.43) | LMNAHTTHHATCYP2D6STAT3 | |
| SCHEMBL30794541 | 0.89 | LMNA (0.46) | LMNAHTTTAAR1POLBL3MBTL1 | |
| SCHEMBL3237106 | 0.89 | LMNA (0.46) | LMNAHTTTAAR1POLBL3MBTL1 | |
| SCHEMBL3242998 | 0.85 | HHAT (0.54) | LMNAHTTPOLBL3MBTL1HHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367700-B2 | Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-02-05 | — | — | US | claimed |
| US-20100152234-A1 | Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2010-06-17 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-8367700-B2 | Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-02-05 | — | — | US | disclosed |
| US-20100152234-A1 | Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152234-A1 | Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | KCNAB1, KCNQ2, KCNQ1 | LMNA 2050/4885HTT 2091/4885TAAR1 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.